Published in Exp Dermatol on February 01, 2011
Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev (2013) 1.12
TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus. PLoS One (2012) 0.87
The burn wound exudate-an under-utilized resource. Burns (2014) 0.84
FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious control. Front Immunol (2012) 0.77
Drug induced exfoliative dermatitis: state of the art. Clin Mol Allergy (2016) 0.76
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. Curr Biol (2005) 4.04
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol (2007) 3.58
Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol (2007) 2.77
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol (2010) 2.67
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49
A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med (2007) 2.41
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol (2004) 2.33
NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. J Invest Dermatol (2010) 2.25
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Facial aesthetic unit remodeling procedure for neurofibromatosis type 1 hemifacial hypertrophy: report on 33 consecutive adult patients. Plast Reconstr Surg (2010) 2.09
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects. JAMA Dermatol (2013) 1.98
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A (2012) 1.97
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol (2003) 1.94
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle (2011) 1.90
Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol (2009) 1.86
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol (2011) 1.85
Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet (2008) 1.73
Granuloma faciale: a clinicopathologic study of 66 patients. J Am Acad Dermatol (2005) 1.70
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A (2007) 1.68
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67
Is a miliary chest pattern always indicative of tuberculosis or malignancy? Respiration (2006) 1.67
Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol (2009) 1.66
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol (2007) 1.60
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53
Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol (2003) 1.53
Prognostic value of skin manifestations of infective endocarditis. JAMA Dermatol (2014) 1.51
Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry A (2014) 1.48
Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol (2006) 1.46
Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med (2014) 1.46
Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients. J Invest Dermatol (2005) 1.44
Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J (2002) 1.35
SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol (2008) 1.33
Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis (2012) 1.32
Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol (2002) 1.32
The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J (2002) 1.30
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol (2013) 1.28
Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy. J Immunol (2008) 1.28
CD molecules 2005: human cell differentiation molecules. Blood (2005) 1.27
BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood (2008) 1.27
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol (2009) 1.26
CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 1.26
Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J (2002) 1.24
CD molecules 2006--human cell differentiation molecules. J Immunol Methods (2006) 1.23
Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab (2004) 1.22
Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol (2010) 1.22
SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol (2006) 1.21
Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol (2005) 1.18
Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res (2013) 1.16
Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst (2011) 1.16
Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med (2006) 1.16
Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis (2011) 1.16
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med (2013) 1.15
The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. Eur J Immunol (2006) 1.15
Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. Int Immunol (2005) 1.13
Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood (2006) 1.13
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol (2013) 1.12
IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A (2009) 1.11
French people and skin diseases: results of a survey using a representative sample. Arch Dermatol (2003) 1.11
Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review. Medicine (Baltimore) (2015) 1.11
Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A (2011) 1.10
Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol (2004) 1.09
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol (2006) 1.08